sales@marketresearchvision.com

30 mins free consultation for each report        Upto 50% Discounts for Highest selling reports


Global Neurodegenerative Drugs Market Trends By Regional Analysis (America, Europe, Asia Pacific, and Middle East & Africa) Growth Opportunity and Industry Forecast 2020-2027

Global Neurodegenerative Drugs Market Trends By Regional Analysis (America, Europe, Asia Pacific, and Middle East & Africa) Growth Opportunity and Industry Forecast 2020-2027

Category : Pharmaceuticals and Healthcare QY Research Pages :117
Published Date : 2020-12-15

 

Covid-19

COVID-19

Understand the influence of COVID-19 on the Neurodegenerative Drugs Market with our analysts monitoring the situation across the globe.
Neurodegenerative Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026. Segment by Type, the Neurodegenerative Drugs market is segmented into NMDA SSRIs Dopamine Inhibitors Segment by Application, the Neurodegenerative Drugs market is segmented into Parkinson’s Disease Huntington Disease Amyotrophic Lateral Sclerosis Alzheimer’s Disease Regional and Country-level Analysis The Neurodegenerative Drugs market is analysed and market size information is provided by regions (countries). The key regions covered in the Neurodegenerative Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026. Competitive Landscape and Neurodegenerative Drugs Market Share Analysis Neurodegenerative Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neurodegenerative Drugs business, the date to enter into the Neurodegenerative Drugs market, Neurodegenerative Drugs product introduction, recent developments, etc. The major vendors covered: Novartis Pfizer Merck Serono Biogen Idec TEVA UCB Boehringer Ingelheim Sanofi GlaxoSmithKline
1 Study Coverage 1.1 Neurodegenerative Drugs Product Introduction 1.2 Market Segments 1.3 Key Neurodegenerative Drugs Manufacturers Covered: Ranking by Revenue 1.4 Market by Type 1.4.1 Global Neurodegenerative Drugs Market Size Growth Rate by Type 1.4.2 NMDA 1.4.3 SSRIs 1.4.4 Dopamine Inhibitors 1.5 Market by Application 1.5.1 Global Neurodegenerative Drugs Market Size Growth Rate by Application 1.5.2 Parkinson’s Disease 1.5.3 Huntington Disease 1.5.4 Amyotrophic Lateral Sclerosis 1.5.5 Alzheimer’s Disease 1.6 Study Objectives 1.7 Years Considered 2 Executive Summary 2.1 Global Neurodegenerative Drugs Market Size, Estimates and Forecasts 2.1.1 Global Neurodegenerative Drugs Revenue 2015-2026 2.1.2 Global Neurodegenerative Drugs Sales 2015-2026 2.2 Global Neurodegenerative Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026 2.2.1 Global Neurodegenerative Drugs Retrospective Market Scenario in Sales by Region: 2015-2020 2.2.2 Global Neurodegenerative Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Neurodegenerative Drugs Competitor Landscape by Players 3.1 Neurodegenerative Drugs Sales by Manufacturers 3.1.1 Neurodegenerative Drugs Sales by Manufacturers (2015-2020) 3.1.2 Neurodegenerative Drugs Sales Market Share by Manufacturers (2015-2020) 3.2 Neurodegenerative Drugs Revenue by Manufacturers 3.2.1 Neurodegenerative Drugs Revenue by Manufacturers (2015-2020) 3.2.2 Neurodegenerative Drugs Revenue Share by Manufacturers (2015-2020) 3.2.3 Global Neurodegenerative Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020) 3.2.4 Global Top 10 and Top 5 Companies by Neurodegenerative Drugs Revenue in 2019 3.2.5 Global Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Neurodegenerative Drugs Price by Manufacturers 3.4 Neurodegenerative Drugs Manufacturing Base Distribution, Product Types 3.4.1 Neurodegenerative Drugs Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Neurodegenerative Drugs Product Type 3.4.3 Date of International Manufacturers Enter into Neurodegenerative Drugs Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026) 4.1 Global Neurodegenerative Drugs Market Size by Type (2015-2020) 4.1.1 Global Neurodegenerative Drugs Sales by Type (2015-2020) 4.1.2 Global Neurodegenerative Drugs Revenue by Type (2015-2020) 4.1.3 Neurodegenerative Drugs Average Selling Price (ASP) by Type (2015-2026) 4.2 Global Neurodegenerative Drugs Market Size Forecast by Type (2021-2026) 4.2.1 Global Neurodegenerative Drugs Sales Forecast by Type (2021-2026) 4.2.2 Global Neurodegenerative Drugs Revenue Forecast by Type (2021-2026) 4.2.3 Neurodegenerative Drugs Average Selling Price (ASP) Forecast by Type (2021-2026) 4.3 Global Neurodegenerative Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Market Size by Application (2015-2026) 5.1 Global Neurodegenerative Drugs Market Size by Application (2015-2020) 5.1.1 Global Neurodegenerative Drugs Sales by Application (2015-2020) 5.1.2 Global Neurodegenerative Drugs Revenue by Application (2015-2020) 5.1.3 Neurodegenerative Drugs Price by Application (2015-2020) 5.2 Neurodegenerative Drugs Market Size Forecast by Application (2021-2026) 5.2.1 Global Neurodegenerative Drugs Sales Forecast by Application (2021-2026) 5.2.2 Global Neurodegenerative Drugs Revenue Forecast by Application (2021-2026) 5.2.3 Global Neurodegenerative Drugs Price Forecast by Application (2021-2026) 6 North America 6.1 North America Neurodegenerative Drugs by Country 6.1.1 North America Neurodegenerative Drugs Sales by Country 6.1.2 North America Neurodegenerative Drugs Revenue by Country 6.1.3 U.S. 6.1.4 Canada 6.2 North America Neurodegenerative Drugs Market Facts & Figures by Type 6.3 North America Neurodegenerative Drugs Market Facts & Figures by Application 7 Europe 7.1 Europe Neurodegenerative Drugs by Country 7.1.1 Europe Neurodegenerative Drugs Sales by Country 7.1.2 Europe Neurodegenerative Drugs Revenue by Country 7.1.3 Germany 7.1.4 France 7.1.5 U.K. 7.1.6 Italy 7.1.7 Russia 7.2 Europe Neurodegenerative Drugs Market Facts & Figures by Type 7.3 Europe Neurodegenerative Drugs Market Facts & Figures by Application 8 Asia Pacific 8.1 Asia Pacific Neurodegenerative Drugs by Region 8.1.1 Asia Pacific Neurodegenerative Drugs Sales by Region 8.1.2 Asia Pacific Neurodegenerative Drugs Revenue by Region 8.1.3 China 8.1.4 Japan 8.1.5 South Korea 8.1.6 India 8.1.7 Australia 8.1.8 Taiwan 8.1.9 Indonesia 8.1.10 Thailand 8.1.11 Malaysia 8.1.12 Philippines 8.1.13 Vietnam 8.2 Asia Pacific Neurodegenerative Drugs Market Facts & Figures by Type 8.3 Asia Pacific Neurodegenerative Drugs Market Facts & Figures by Application 9 Latin America 9.1 Latin America Neurodegenerative Drugs by Country 9.1.1 Latin America Neurodegenerative Drugs Sales by Country 9.1.2 Latin America Neurodegenerative Drugs Revenue by Country 9.1.3 Mexico 9.1.4 Brazil 9.1.5 Argentina 9.2 Central & South America Neurodegenerative Drugs Market Facts & Figures by Type 9.3 Central & South America Neurodegenerative Drugs Market Facts & Figures by Application 10 Middle East and Africa 10.1 Middle East and Africa Neurodegenerative Drugs by Country 10.1.1 Middle East and Africa Neurodegenerative Drugs Sales by Country 10.1.2 Middle East and Africa Neurodegenerative Drugs Revenue by Country 10.1.3 Turkey 10.1.4 Saudi Arabia 10.1.5 U.A.E 10.2 Middle East and Africa Neurodegenerative Drugs Market Facts & Figures by Type 10.3 Middle East and Africa Neurodegenerative Drugs Market Facts & Figures by Application 11 Company Profiles 11.1 Novartis 11.1.1 Novartis Corporation Information 11.1.2 Novartis Description and Business Overview 11.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Novartis Neurodegenerative Drugs Products Offered 11.1.5 Novartis Related Developments 11.2 Pfizer 11.2.1 Pfizer Corporation Information 11.2.2 Pfizer Description and Business Overview 11.2.3 Pfizer Sales, Revenue and Gross Margin (2015-2020) 11.2.4 Pfizer Neurodegenerative Drugs Products Offered 11.2.5 Pfizer Related Developments 11.3 Merck Serono 11.3.1 Merck Serono Corporation Information 11.3.2 Merck Serono Description and Business Overview 11.3.3 Merck Serono Sales, Revenue and Gross Margin (2015-2020) 11.3.4 Merck Serono Neurodegenerative Drugs Products Offered 11.3.5 Merck Serono Related Developments 11.4 Biogen Idec 11.4.1 Biogen Idec Corporation Information 11.4.2 Biogen Idec Description and Business Overview 11.4.3 Biogen Idec Sales, Revenue and Gross Margin (2015-2020) 11.4.4 Biogen Idec Neurodegenerative Drugs Products Offered 11.4.5 Biogen Idec Related Developments 11.5 TEVA 11.5.1 TEVA Corporation Information 11.5.2 TEVA Description and Business Overview 11.5.3 TEVA Sales, Revenue and Gross Margin (2015-2020) 11.5.4 TEVA Neurodegenerative Drugs Products Offered 11.5.5 TEVA Related Developments 11.6 UCB 11.6.1 UCB Corporation Information 11.6.2 UCB Description and Business Overview 11.6.3 UCB Sales, Revenue and Gross Margin (2015-2020) 11.6.4 UCB Neurodegenerative Drugs Products Offered 11.6.5 UCB Related Developments 11.7 Boehringer Ingelheim 11.7.1 Boehringer Ingelheim Corporation Information 11.7.2 Boehringer Ingelheim Description and Business Overview 11.7.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020) 11.7.4 Boehringer Ingelheim Neurodegenerative Drugs Products Offered 11.7.5 Boehringer Ingelheim Related Developments 11.8 Sanofi 11.8.1 Sanofi Corporation Information 11.8.2 Sanofi Description and Business Overview 11.8.3 Sanofi Sales, Revenue and Gross Margin (2015-2020) 11.8.4 Sanofi Neurodegenerative Drugs Products Offered 11.8.5 Sanofi Related Developments 11.9 GlaxoSmithKline 11.9.1 GlaxoSmithKline Corporation Information 11.9.2 GlaxoSmithKline Description and Business Overview 11.9.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020) 11.9.4 GlaxoSmithKline Neurodegenerative Drugs Products Offered 11.9.5 GlaxoSmithKline Related Developments 11.1 Novartis 11.1.1 Novartis Corporation Information 11.1.2 Novartis Description and Business Overview 11.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Novartis Neurodegenerative Drugs Products Offered 11.1.5 Novartis Related Developments 12 Future Forecast by Regions (Countries) (2021-2026) 12.1 Neurodegenerative Drugs Market Estimates and Projections by Region 12.1.1 Global Neurodegenerative Drugs Sales Forecast by Regions 2021-2026 12.1.2 Global Neurodegenerative Drugs Revenue Forecast by Regions 2021-2026 12.2 North America Neurodegenerative Drugs Market Size Forecast (2021-2026) 12.2.1 North America: Neurodegenerative Drugs Sales Forecast (2021-2026) 12.2.2 North America: Neurodegenerative Drugs Revenue Forecast (2021-2026) 12.2.3 North America: Neurodegenerative Drugs Market Size Forecast by Country (2021-2026) 12.3 Europe Neurodegenerative Drugs Market Size Forecast (2021-2026) 12.3.1 Europe: Neurodegenerative Drugs Sales Forecast (2021-2026) 12.3.2 Europe: Neurodegenerative Drugs Revenue Forecast (2021-2026) 12.3.3 Europe: Neurodegenerative Drugs Market Size Forecast by Country (2021-2026) 12.4 Asia Pacific Neurodegenerative Drugs Market Size Forecast (2021-2026) 12.4.1 Asia Pacific: Neurodegenerative Drugs Sales Forecast (2021-2026) 12.4.2 Asia Pacific: Neurodegenerative Drugs Revenue Forecast (2021-2026) 12.4.3 Asia Pacific: Neurodegenerative Drugs Market Size Forecast by Region (2021-2026) 12.5 Latin America Neurodegenerative Drugs Market Size Forecast (2021-2026) 12.5.1 Latin America: Neurodegenerative Drugs Sales Forecast (2021-2026) 12.5.2 Latin America: Neurodegenerative Drugs Revenue Forecast (2021-2026) 12.5.3 Latin America: Neurodegenerative Drugs Market Size Forecast by Country (2021-2026) 12.6 Middle East and Africa Neurodegenerative Drugs Market Size Forecast (2021-2026) 12.6.1 Middle East and Africa: Neurodegenerative Drugs Sales Forecast (2021-2026) 12.6.2 Middle East and Africa: Neurodegenerative Drugs Revenue Forecast (2021-2026) 12.6.3 Middle East and Africa: Neurodegenerative Drugs Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 13.1 Market Opportunities and Drivers 13.2 Market Challenges 13.3 Market Risks/Restraints 13.4 Porter's Five Forces Analysis 13.5 Primary Interviews with Key Neurodegenerative Drugs Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis 14.2 Neurodegenerative Drugs Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details 16.3 Disclaimer

Get Free Sample

List of Tables Table 1. Neurodegenerative Drugs Market Segments Table 2. Ranking of Global Top Neurodegenerative Drugs Manufacturers by Revenue (US$ Million) in 2019 Table 3. Global Neurodegenerative Drugs Market Size Growth Rate by Type 2020-2026 (MT) & (US$ Million) Table 4. Major Manufacturers of NMDA Table 5. Major Manufacturers of SSRIs Table 6. Major Manufacturers of Dopamine Inhibitors Table 7. Global Neurodegenerative Drugs Market Size Growth Rate by Application 2020-2026 (MT) Table 8. Global Neurodegenerative Drugs Market Size by Region (MT) & (US$ Million): 2020 VS 2026 Table 9. Global Neurodegenerative Drugs Sales by Regions 2015-2020 (MT) Table 10. Global Neurodegenerative Drugs Sales Market Share by Regions (2015-2020) Table 11. Global Neurodegenerative Drugs Revenue by Regions 2015-2020 (US$ Million) Table 12. Global Neurodegenerative Drugs Sales by Manufacturers (2015-2020) (MT) Table 13. Global Neurodegenerative Drugs Sales Share by Manufacturers (2015-2020) Table 14. Global Neurodegenerative Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020) Table 15. Global Neurodegenerative Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Drugs as of 2019) Table 16. Neurodegenerative Drugs Revenue by Manufacturers (2015-2020) (US$ Million) Table 17. Neurodegenerative Drugs Revenue Share by Manufacturers (2015-2020) Table 18. Key Manufacturers Neurodegenerative Drugs Price (2015-2020) (USD/MT) Table 19. Neurodegenerative Drugs Manufacturers Manufacturing Base Distribution and Headquarters Table 20. Manufacturers Neurodegenerative Drugs Product Type Table 21. Date of International Manufacturers Enter into Neurodegenerative Drugs Market Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans Table 23. Global Neurodegenerative Drugs Sales by Type (2015-2020) (MT) Table 24. Global Neurodegenerative Drugs Sales Share by Type (2015-2020) Table 25. Global Neurodegenerative Drugs Revenue by Type (2015-2020) (US$ Million) Table 26. Global Neurodegenerative Drugs Revenue Share by Type (2015-2020) Table 27. Neurodegenerative Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT) Table 28. Global Neurodegenerative Drugs Sales by Application (2015-2020) (MT) Table 29. Global Neurodegenerative Drugs Sales Share by Application (2015-2020) Table 30. North America Neurodegenerative Drugs Sales by Country (2015-2020) (MT) Table 31. North America Neurodegenerative Drugs Sales Market Share by Country (2015-2020) Table 32. North America Neurodegenerative Drugs Revenue by Country (2015-2020) (US$ Million) Table 33. North America Neurodegenerative Drugs Revenue Market Share by Country (2015-2020) Table 34. North America Neurodegenerative Drugs Sales by Type (2015-2020) (MT) Table 35. North America Neurodegenerative Drugs Sales Market Share by Type (2015-2020) Table 36. North America Neurodegenerative Drugs Sales by Application (2015-2020) (MT) Table 37. North America Neurodegenerative Drugs Sales Market Share by Application (2015-2020) Table 38. Europe Neurodegenerative Drugs Sales by Country (2015-2020) (MT) Table 39. Europe Neurodegenerative Drugs Sales Market Share by Country (2015-2020) Table 40. Europe Neurodegenerative Drugs Revenue by Country (2015-2020) (US$ Million) Table 41. Europe Neurodegenerative Drugs Revenue Market Share by Country (2015-2020) Table 42. Europe Neurodegenerative Drugs Sales by Type (2015-2020) (MT) Table 43. Europe Neurodegenerative Drugs Sales Market Share by Type (2015-2020) Table 44. Europe Neurodegenerative Drugs Sales by Application (2015-2020) (MT) Table 45. Europe Neurodegenerative Drugs Sales Market Share by Application (2015-2020) Table 46. Asia Pacific Neurodegenerative Drugs Sales by Region (2015-2020) (MT) Table 47. Asia Pacific Neurodegenerative Drugs Sales Market Share by Region (2015-2020) Table 48. Asia Pacific Neurodegenerative Drugs Revenue by Region (2015-2020) (US$ Million) Table 49. Asia Pacific Neurodegenerative Drugs Revenue Market Share by Region (2015-2020) Table 50. Asia Pacific Neurodegenerative Drugs Sales by Type (2015-2020) (MT) Table 51. Asia Pacific Neurodegenerative Drugs Sales Market Share by Type (2015-2020) Table 52. Asia Pacific Neurodegenerative Drugs Sales by Application (2015-2020) (MT) Table 53. Asia Pacific Neurodegenerative Drugs Sales Market Share by Application (2015-2020) Table 54. Latin America Neurodegenerative Drugs Sales by Country (2015-2020) (MT) Table 55. Latin America Neurodegenerative Drugs Sales Market Share by Country (2015-2020) Table 56. Latin Americaa Neurodegenerative Drugs Revenue by Country (2015-2020) (US$ Million) Table 57. Latin America Neurodegenerative Drugs Revenue Market Share by Country (2015-2020) Table 58. Latin America Neurodegenerative Drugs Sales by Type (2015-2020) (MT) Table 59. Latin America Neurodegenerative Drugs Sales Market Share by Type (2015-2020) Table 60. Latin America Neurodegenerative Drugs Sales by Application (2015-2020) (MT) Table 61. Latin America Neurodegenerative Drugs Sales Market Share by Application (2015-2020) Table 62. Middle East and Africa Neurodegenerative Drugs Sales by Country (2015-2020) (MT) Table 63. Middle East and Africa Neurodegenerative Drugs Sales Market Share by Country (2015-2020) Table 64. Middle East and Africa Neurodegenerative Drugs Revenue by Country (2015-2020) (US$ Million) Table 65. Middle East and Africa Neurodegenerative Drugs Revenue Market Share by Country (2015-2020) Table 66. Middle East and Africa Neurodegenerative Drugs Sales by Type (2015-2020) (MT) Table 67. Middle East and Africa Neurodegenerative Drugs Sales Market Share by Type (2015-2020) Table 68. Middle East and Africa Neurodegenerative Drugs Sales by Application (2015-2020) (MT) Table 69. Middle East and Africa Neurodegenerative Drugs Sales Market Share by Application (2015-2020) Table 70. Novartis Corporation Information Table 71. Novartis Description and Major Businesses Table 72. Novartis Neurodegenerative Drugs Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 73. Novartis Product Table 74. Novartis Recent Development Table 75. Pfizer Corporation Information Table 76. Pfizer Description and Major Businesses Table 77. Pfizer Neurodegenerative Drugs Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 78. Pfizer Product Table 79. Pfizer Recent Development Table 80. Merck Serono Corporation Information Table 81. Merck Serono Description and Major Businesses Table 82. Merck Serono Neurodegenerative Drugs Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 83. Merck Serono Product Table 84. Merck Serono Recent Development Table 85. Biogen Idec Corporation Information Table 86. Biogen Idec Description and Major Businesses Table 87. Biogen Idec Neurodegenerative Drugs Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 88. Biogen Idec Product Table 89. Biogen Idec Recent Development Table 90. TEVA Corporation Information Table 91. TEVA Description and Major Businesses Table 92. TEVA Neurodegenerative Drugs Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 93. TEVA Product Table 94. TEVA Recent Development Table 95. UCB Corporation Information Table 96. UCB Description and Major Businesses Table 97. UCB Neurodegenerative Drugs Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 98. UCB Product Table 99. UCB Recent Development Table 100. Boehringer Ingelheim Corporation Information Table 101. Boehringer Ingelheim Description and Major Businesses Table 102. Boehringer Ingelheim Neurodegenerative Drugs Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 103. Boehringer Ingelheim Product Table 104. Boehringer Ingelheim Recent Development Table 105. Sanofi Corporation Information Table 106. Sanofi Description and Major Businesses Table 107. Sanofi Neurodegenerative Drugs Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 108. Sanofi Product Table 109. Sanofi Recent Development Table 110. GlaxoSmithKline Corporation Information Table 111. GlaxoSmithKline Description and Major Businesses Table 112. GlaxoSmithKline Neurodegenerative Drugs Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 113. GlaxoSmithKline Product Table 114. GlaxoSmithKline Recent Development Table 115. Global Neurodegenerative Drugs Sales Forecast by Regions (2021-2026) (MT) Table 116. Global Neurodegenerative Drugs Sales Market Share Forecast by Regions (2021-2026) Table 117. Global Neurodegenerative Drugs Revenue Forecast by Regions (2021-2026) (US$ Million) Table 118. Global Neurodegenerative Drugs Revenue Market Share Forecast by Regions (2021-2026) Table 119. North America: Neurodegenerative Drugs Sales Forecast by Country (2021-2026) (MT) Table 120. North America: Neurodegenerative Drugs Revenue Forecast by Country (2021-2026) (US$ Million) Table 121. Europe: Neurodegenerative Drugs Sales Forecast by Country (2021-2026) (MT) Table 122. Europe: Neurodegenerative Drugs Revenue Forecast by Country (2021-2026) (US$ Million) Table 123. Asia Pacific: Neurodegenerative Drugs Sales Forecast by Region (2021-2026) (MT) Table 124. Asia Pacific: Neurodegenerative Drugs Revenue Forecast by Region (2021-2026) (US$ Million) Table 125. Latin America: Neurodegenerative Drugs Sales Forecast by Country (2021-2026) (MT) Table 126. Latin America: Neurodegenerative Drugs Revenue Forecast by Country (2021-2026) (US$ Million) Table 127. Middle East and Africa: Neurodegenerative Drugs Sales Forecast by Country (2021-2026) (MT) Table 128. Middle East and Africa: Neurodegenerative Drugs Revenue Forecast by Country (2021-2026) (US$ Million) Table 129. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 130. Key Challenges Table 131. Market Risks Table 132. Main Points Interviewed from Key Neurodegenerative Drugs Players Table 133. Neurodegenerative Drugs Customers List Table 134. Neurodegenerative Drugs Distributors List Table 135. Research Programs/Design for This Report Table 136. Key Data Information from Secondary Sources Table 137. Key Data Information from Primary Sources List of Figures Figure 1. Neurodegenerative Drugs Product Picture Figure 2. Global Neurodegenerative Drugs Sales Market Share by Type in 2020 & 2026 Figure 3. NMDA Product Picture Figure 4. SSRIs Product Picture Figure 5. Dopamine Inhibitors Product Picture Figure 6. Global Neurodegenerative Drugs Sales Market Share by Application in 2020 & 2026 Figure 7. Parkinson’s Disease Figure 8. Huntington Disease Figure 9. Amyotrophic Lateral Sclerosis Figure 10. Alzheimer’s Disease Figure 11. Neurodegenerative Drugs Report Years Considered Figure 12. Global Neurodegenerative Drugs Market Size 2015-2026 (US$ Million) Figure 13. Global Neurodegenerative Drugs Sales 2015-2026 (MT) Figure 14. Global Neurodegenerative Drugs Market Size Market Share by Region: 2020 Versus 2026 Figure 15. Global Neurodegenerative Drugs Sales Market Share by Region (2015-2020) Figure 16. Global Neurodegenerative Drugs Sales Market Share by Region in 2019 Figure 17. Global Neurodegenerative Drugs Revenue Market Share by Region (2015-2020) Figure 18. Global Neurodegenerative Drugs Revenue Market Share by Region in 2019 Figure 19. Global Neurodegenerative Drugs Sales Share by Manufacturer in 2019 Figure 20. The Top 10 and 5 Players Market Share by Neurodegenerative Drugs Revenue in 2019 Figure 21. Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 22. Global Neurodegenerative Drugs Sales Market Share by Type (2015-2020) Figure 23. Global Neurodegenerative Drugs Sales Market Share by Type in 2019 Figure 24. Global Neurodegenerative Drugs Revenue Market Share by Type (2015-2020) Figure 25. Global Neurodegenerative Drugs Revenue Market Share by Type in 2019 Figure 26. Global Neurodegenerative Drugs Market Share by Price Range (2015-2020) Figure 27. Global Neurodegenerative Drugs Sales Market Share by Application (2015-2020) Figure 28. Global Neurodegenerative Drugs Sales Market Share by Application in 2019 Figure 29. Global Neurodegenerative Drugs Revenue Market Share by Application (2015-2020) Figure 30. Global Neurodegenerative Drugs Revenue Market Share by Application in 2019 Figure 31. North America Neurodegenerative Drugs Sales Growth Rate 2015-2020 (MT) Figure 32. North America Neurodegenerative Drugs Revenue Growth Rate 2015-2020 (US$ Million) Figure 33. North America Neurodegenerative Drugs Sales Market Share by Country in 2019 Figure 34. North America Neurodegenerative Drugs Revenue Market Share by Country in 2019 Figure 35. U.S. Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 36. U.S. Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 37. Canada Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 38. Canada Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 39. North America Neurodegenerative Drugs Market Share by Type in 2019 Figure 40. North America Neurodegenerative Drugs Market Share by Application in 2019 Figure 41. Europe Neurodegenerative Drugs Sales Growth Rate 2015-2020 (MT) Figure 42. Europe Neurodegenerative Drugs Revenue Growth Rate 2015-2020 (US$ Million) Figure 43. Europe Neurodegenerative Drugs Sales Market Share by Country in 2019 Figure 44. Europe Neurodegenerative Drugs Revenue Market Share by Country in 2019 Figure 45. Germany Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 46. Germany Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 47. France Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 48. France Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 49. U.K. Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 50. U.K. Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 51. Italy Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 52. Italy Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 53. Russia Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 54. Russia Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 55. Europe Neurodegenerative Drugs Market Share by Type in 2019 Figure 56. Europe Neurodegenerative Drugs Market Share by Application in 2019 Figure 57. Asia Pacific Neurodegenerative Drugs Sales Growth Rate 2015-2020 (MT) Figure 58. Asia Pacific Neurodegenerative Drugs Revenue Growth Rate 2015-2020 (US$ Million) Figure 59. Asia Pacific Neurodegenerative Drugs Sales Market Share by Region in 2019 Figure 60. Asia Pacific Neurodegenerative Drugs Revenue Market Share by Region in 2019 Figure 61. China Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 62. China Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 63. Japan Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 64. Japan Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 65. South Korea Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 66. South Korea Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 67. India Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 68. India Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 69. Australia Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 70. Australia Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 71. Taiwan Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 72. Taiwan Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 73. Indonesia Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 74. Indonesia Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 75. Thailand Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 76. Thailand Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 77. Malaysia Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 78. Malaysia Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 79. Philippines Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 80. Philippines Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 81. Vietnam Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 82. Vietnam Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 83. Asia Pacific Neurodegenerative Drugs Market Share by Type in 2019 Figure 84. Asia Pacific Neurodegenerative Drugs Market Share by Application in 2019 Figure 85. Latin America Neurodegenerative Drugs Sales Growth Rate 2015-2020 (MT) Figure 86. Latin America Neurodegenerative Drugs Revenue Growth Rate 2015-2020 (US$ Million) Figure 87. Latin America Neurodegenerative Drugs Sales Market Share by Country in 2019 Figure 88. Latin America Neurodegenerative Drugs Revenue Market Share by Country in 2019 Figure 89. Mexico Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 90. Mexico Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 91. Brazil Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 92. Brazil Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 93. Argentina Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 94. Argentina Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 95. Latin America Neurodegenerative Drugs Market Share by Type in 2019 Figure 96. Latin America Neurodegenerative Drugs Market Share by Application in 2019 Figure 97. Middle East and Africa Neurodegenerative Drugs Sales Growth Rate 2015-2020 (MT) Figure 98. Middle East and Africa Neurodegenerative Drugs Revenue Growth Rate 2015-2020 (US$ Million) Figure 99. Middle East and Africa Neurodegenerative Drugs Sales Market Share by Country in 2019 Figure 100. Middle East and Africa Neurodegenerative Drugs Revenue Market Share by Country in 2019 Figure 101. Turkey Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 102. Turkey Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 103. Saudi Arabia Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 104. Saudi Arabia Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 105. U.A.E Neurodegenerative Drugs Sales Growth Rate (2015-2020) (MT) Figure 106. U.A.E Neurodegenerative Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 107. Middle East and Africa Neurodegenerative Drugs Market Share by Type in 2019 Figure 108. Middle East and Africa Neurodegenerative Drugs Market Share by Application in 2019 Figure 109. North America Neurodegenerative Drugs Sales Growth Rate Forecast (2021-2026) (MT) Figure 110. North America Neurodegenerative Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 111. Europe Neurodegenerative Drugs Sales Growth Rate Forecast (2021-2026) (MT) Figure 112. Europe Neurodegenerative Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 113. Asia Pacific Neurodegenerative Drugs Sales Growth Rate Forecast (2021-2026) (MT) Figure 114. Asia Pacific Neurodegenerative Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 115. Latin America Neurodegenerative Drugs Sales Growth Rate Forecast (2021-2026) (MT) Figure 116. Latin America Neurodegenerative Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 117. Middle East and Africa Neurodegenerative Drugs Sales Growth Rate Forecast (2021-2026) (MT) Figure 118. Middle East and Africa Neurodegenerative Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 119. Porter's Five Forces Analysis Figure 120. Channels of Distribution Figure 121. Distributors Profiles Figure 122. Bottom-up and Top-down Approaches for This Report Figure 123. Data Triangulation Figure 124. Key Executives Interviewed

Get Free Sample

Related Reports

Global Neurodegenerative Drugs Market Trends By Regional Analysis (America, Europe, Asia Pacific, and Middle East & Africa) Growth Opportunity and Industry Forecast 2020-2027

Global Cushing's Syndrome Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

Cushing's syndrome involves symptoms such as high blood pressure, abdominal obesity, round red face, a fatty lump between the shoulders, weak muscles and bones, acne, fragile skin and others. Most ...
read more

Global Neurodegenerative Drugs Market Trends By Regional Analysis (America, Europe, Asia Pacific, and Middle East & Africa) Growth Opportunity and Industry Forecast 2020-2027

Global Tyrosine Kinase Inhibitors Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Tyrosine kinase inhibitors are small molecules that bind to the receptor site of the kinase enzyme available at cell surface. Scope of the Report: The global tyrosine kinase inhibitors market is e ...
read more

Global Neurodegenerative Drugs Market Trends By Regional Analysis (America, Europe, Asia Pacific, and Middle East & Africa) Growth Opportunity and Industry Forecast 2020-2027

Global 2D Chromatography Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

2D chromatography is a type of chromatographic technique in which the injected sample is separated by passing through two different separation stages. This is done by injecting the eluent from the fir ...
read more

Global Neurodegenerative Drugs Market Trends By Regional Analysis (America, Europe, Asia Pacific, and Middle East & Africa) Growth Opportunity and Industry Forecast 2020-2027

Global Astringent Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Astringent are used as an adjunct or alternative to standard suturing techniques to control bleeding or for wound closure. Scope of the Report: In 2018, North America is expected to account for th ...
read more

Global Neurodegenerative Drugs Market Trends By Regional Analysis (America, Europe, Asia Pacific, and Middle East & Africa) Growth Opportunity and Industry Forecast 2020-2027

Global Disintegrants Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Disintegrants are agents added to tablet (and some encapsulated) formulations to promote the breakup of the tablet (and capsule “slugs') into smaller fragments in an aqueous environment thereby ...
read more


Choose License Type

Single User - This is a single user license, allowing one specific user access to the product.

Multi User - This is a 1-5 user licence, allowing up to five users have access to the product.

Enterprise User - This is an enterprise license, allowing all employees within your organisation access to the product. The report will be emailed to you.


Cards For Payment

Why Choose us

  • Lowest Price Guarantee
  • We offer the lowest prices for the listed reports
  • Data Security
  • Your data is safe and secure
  • Vast Report Database
  • We have more than 2 Million reports in our database
  • Client Focused
  • Personalized updates and 24*7 support
  • Trusted Source and Quality
  • We only work with reputable partners providing high quality research and support
  • Market Segmentation
  • We provide alternative views of the market to help you identify where the real opportunities lie
  • Bulk Discounts
  • We offer great discounts on purchase of multiple reports

Testimonials

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed.
-VP of a Automotive division in Germany

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements
-Product Manager at US based Manufacturer

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process
-Marketing Manager at a pharma company in Belgium

How To Reach Us

Reach out to our most senior Sales Professional-
Jay Matthews

+1 513 549 5911 (U.S.),
    +44 203 318 2846 (U.K.)
sales@marketresearchvision.com
 

Our Clients






Market Research Vision

About Us


Market Research Vision is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports. Serving as a market research firm, we help our clients in finding: what’s next? We believe in finding creative and innovative solutions through customized and syndicated research reports.
Read More


Contact Us


 
sales@marketresearchvision.com


+1 513 549 5911 (U.S.)
+44 203 318 2846 (U.K.)